LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

Search

Stryker Corp

Gesloten

SectorGezondheidszorg

363.69 2.57

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

353.71

Max

363.87

Belangrijke statistieken

By Trading Economics

Inkomsten

-25M

859M

Verkoop

35M

6.1B

K/W

Sectorgemiddelde

47.188

77.256

EPS

3.19

Dividendrendement

0.94

Winstmarge

14.182

Werknemers

53,000

EBITDA

-108M

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+20.94% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.94%

2.33%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-9.7B

137B

Vorige openingsprijs

361.12

Vorige sluitingsprijs

363.69

Nieuwssentiment

By Acuity

23%

77%

57 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Stryker Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 okt 2025, 20:36 UTC

Winsten

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

31 jul 2025, 20:42 UTC

Winsten

Stryker Lifts Guidance on Improving Tariff Outlook

1 mei 2025, 20:56 UTC

Winsten

Stryker Lowers Adjusted EPS View on $200 Million Tariff Impact

5 nov 2025, 19:38 UTC

Winsten

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5 nov 2025, 17:00 UTC

Winsten

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

30 okt 2025, 20:21 UTC

Winsten

Stryker Lifts FY Sales View After 3Q Revenue Rises

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.1B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.50-Adj EPS $13.60 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.06B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

31 jul 2025, 20:09 UTC

Winsten

Stryker Sales >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Net $884M >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Adj EPS $3.13 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

1 mei 2025, 20:41 UTC

Winsten

Stryker Lowers Adjusted EPS View on $200M Tariff Impact

1 mei 2025, 20:11 UTC

Winsten

Stryker Cuts FY25 View To Adj EPS $13.20-Adj EPS $13.45 >SYK

1 mei 2025, 20:10 UTC

Winsten

Stryker Raising FY25 Organic Net Sales Growth Guidance Range to 8.5% to 9.5% >SYK

1 mei 2025, 20:05 UTC

Winsten

Stryker 1Q Adj EPS $2.84 >SYK

Peer Vergelijking

Prijswijziging

Stryker Corp Prognose

Koersdoel

By TipRanks

20.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 430.6 USD  20.94%

Hoogste 455 USD

Laagste 392 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Stryker Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technische score

By Trading Central

373.92 / 383.99Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

57 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
help-icon Live chat